Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
toripalimab + gemcitabine
- Development stage
- Phase 3
- Lead developer
- Junshi Biosciences
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Toripalimab + gemcitabine is a combination therapy consisting of toripalimab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1), and gemcitabine, a nucleoside analog used as chemotherapy. Toripalimab blocks the PD-1 receptor on T cells to enhance immune-mediated tumor cell killing by preventing interaction with its ligands PD-L1 and PD-L2. Gemcitabine inhibits DNA synthesis by incorporating into DNA during replication, leading to apoptosis in rapidly dividing cancer cells. This combination has been studied primarily for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), especially in patients who are ineligible for cisplatin-based regimens or as part of first-line therapy. Clinical trials have shown that this regimen offers favorable response rates and improved survival outcomes with manageable toxicity profiles[1][2][3].
- Other names
- Toripalimab and Gemcitabine based therapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on toripalimab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on toripalimab + gemcitabine.